(Q37207935)

English

Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy

scientific article published on 16 December 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

18 August 2017

Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy (English)

1 reference

Europe PubMed Central

18 August 2017

colorectal cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

colorectal carcinoma

1 reference

based on heuristic

inferred from title

author name string

Nicolas Tsavaris

1

1 reference

Europe PubMed Central

18 August 2017

Andreas Lazaris

2

1 reference

Europe PubMed Central

18 August 2017

Christos Kosmas

3

1 reference

Europe PubMed Central

18 August 2017

Panagiotis Gouveris

4

1 reference

Europe PubMed Central

18 August 2017

Nikolaos Kavantzas

5

1 reference

Europe PubMed Central

18 August 2017

Petros Kopterides

6

1 reference

Europe PubMed Central

18 August 2017

Thomas Papathomas

7

1 reference

Europe PubMed Central

18 August 2017

George Agrogiannis

8

1 reference

Europe PubMed Central

18 August 2017

Haralambos Zorzos

9

1 reference

Europe PubMed Central

18 August 2017

Vassiliki Kyriakou

10

1 reference

Europe PubMed Central

18 August 2017

Efstratios Patsouris

11

1 reference

Europe PubMed Central

18 August 2017

publication date

16 December 2008

1 reference

Europe PubMed Central

18 August 2017

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

18 August 2017

64

1 reference

Europe PubMed Central

18 August 2017

391-398

1 reference

Europe PubMed Central

18 August 2017

2

1 reference

Europe PubMed Central

18 August 2017

https://scigraph.springernature.com/pub.10.1007/s00280-008-0886-4

0 references

The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Topoisomerase II - drug interaction domains: identification of substituents on etoposide that interact with the enzyme.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Comparative genomic hybridization. Synchronous occurrence of focal nodular hyperplasia and hepatocellular carcinoma in the same liver is not based on common chromosomal aberrations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Immunohistochemical detection of DNA topoisomerase I in formalin fixed, paraffin wax embedded normal tissues and in ovarian carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

A model for the mechanism of human topoisomerase I

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Comparison of topoisomerase II alpha and MIB-1 expression in uterine cervical squamous lesions.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

A phase I-II trial of continuous-infusion cisplatin, continuous-infusion 5-fluorouracil, and VP-16 in colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

6 September 2017

Eukaryotic DNA topoisomerases I.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

14 September 2017

Continuing the fight against advanced colorectal cancer: new and future treatment options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

28 September 2017

DNA topoisomerase I is involved in both repression and activation of transcription

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

26 June 2018

Topoisomerase I gene expression and cell sensitivity to camptothecin in human cell lines of different tumor types.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

26 June 2018

Cisplatin and etoposide in advanced colorectal carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

26 June 2018

Topoisomerase-I, thymidylate synthase primary tumour expression and clinical efficacy of 5-FU/CPT-11 chemotherapy in advanced colorectal cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Immunohistochemical study of DNA topoisomerase I, DNA topoisomerase II alpha, p53, and Ki-67 in oral preneoplastic lesions and oral squamous cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Breast cancer after curative chemotherapy in non-Hodgkin's lymphoma: examination of the role of drug resistance and retrospective comparison to the outcome of de novo breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Two different schedules of irinotecan (CPT-11) in patients with advanced colorectal carcinoma relapsing after a 5-fluorouracil and leucovorin combination. A randomized study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Multidrug resistance proteins and topoisomerase IIalpha expression in colon cancer: association with metastatic potential.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Etoposide, leucovorin (LV) and 5-fluorouracil (5-FU) in 5-FU+LV pre-treated patients with advanced colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Etoposide added to weekly leucovorin (LV)/5-fluorouracil (5-FU) in LV/5-FU pre-treated patients with advanced colorectal cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Human DNA topoisomerase I: An anticancer drug target present in human sarcomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Markers of drug resistance in relapsing colon cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Elevations of DNA topoisomerase I in invasive carcinoma of the breast

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Expression of DNA topoisomerase I in neoplasms of the kidney: correlation with histological grade, proliferation, and patient survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

[Second-line irinotecan chemotherapy in the treatment of metastatic colorectal cancers: phase III trials].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Irinotecan monotherapy in the treatment of colorectal cancers: results of phase II trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Different modes of cell-killing action between DNA topoisomerase I and II inhibitors revealed by kinetic analysis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2688619

3 September 2018

Immunohistochemical staining for DNA topoisomerase I, DNA topoisomerase II-alpha and p53 in gastric carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Purification of DNA topoisomerase I from the spleen of a patient with non-Hodgkin's lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of DNA topoisomerase I and DNA topoisomerase II-alpha in carcinoma of the colon

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A phase I/II trial of 5-fluorouracil and etoposide in metastatic colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevations of DNA topoisomerase I in transitional cell carcinoma of the urinary bladder: correlation with DNA topoisomerase II-alpha and p53 expression

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Synthesis and antitumor activity of novel water soluble derivatives of camptothecin as specific inhibitors of topoisomerase I

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequential administration of 5-fluorouracil (5FU)/leucovorin (LV) followed by irinotecan (CPT-11) at relapse versus CPT-11 followed by 5-FU/LV in advanced colorectal carcinoma. A phase III randomized study.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Carboplatin and etoposide in previously treated colorectal cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical applications of anticancer drugs targeted to topoisomerase II

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Irinotecan is an active agent in untreated patients with metastatic colorectal cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Elevations of DNA topoisomerase I catalytic activity and immunoprotein in human malignancies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cisplatin and chronic oral etoposide as salvage therapy for advanced colorectal carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[Irinotecan: various administration schedules, study of drug combinations, phase I experience]

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase I protein expression in primary colorectal cancer and lymph node metastases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Topoisomerase I protein expression in primary colorectal cancer and recurrences after 5-FU-based adjuvant chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of DNA toposiomerase I and DNA topoisomerase II-alpha in testicular seminomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/19083133

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00280-008-0886-4

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

1 reference

Europe PubMed Central

18 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37207935&oldid=1694478145"